Show simple item record

dc.contributor.authorWatson, H.*
dc.contributor.authorCockbain, A.J.*
dc.contributor.authorSpencer, Jade A.*
dc.contributor.authorRace, Amanda D.*
dc.contributor.authorVolpato, Milène*
dc.contributor.authorLoadman, Paul*
dc.contributor.authorToogood, G.J.*
dc.contributor.authorHull, M.A.*
dc.date.accessioned2016-11-03T10:14:21Z
dc.date.available2016-11-03T10:14:21Z
dc.date.issued2016-12
dc.identifier.citationWatson H, Cockbain AJ, Spencer J et al (2016) Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA). 115: 60-66.
dc.identifier.urihttp://hdl.handle.net/10454/10200
dc.descriptionYes
dc.description.abstractWe investigated red blood cell (RBC) PUFA profiles, and the predictive value of RBC EPA content for tumour EPA exposure and clinical outcomes, in the EMT study, a randomised trial of EPA in patients awaiting colorectal cancer (CRC) liver metastasis surgery (A.J. Cockbain et al., 2014). There was a significant increase in RBC EPA in the EPA group (n=43; median intervention 30 days; mean absolute 1.26 [±0.14]% increase; P<0.001), but not in the placebo arm (n=45). EPA incorporation varied widely in EPA users and was not explained by treatment duration or compliance. There was little evidence of ‘contamination’ in the placebo group. The EPA level predicted tumour EPA content (r=0.36; P=0.03). Participants with post-treatment EPA ≥1.22% (n=49) had improved OS compared with EPA <1.22% (n=29; HR 0.42[95%CI 0.16–0.95]). RBC EPA content should be evaluated as a biomarker of tumour exposure and clinical outcomes in future EPA trials in CRC patients.
dc.language.isoen
dc.rights© 2016 Elsevier. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
dc.subjectColorectal cancer
dc.subjectEicosapentaenoic acid
dc.subjectOmega-3 polyunsaturated fatty acid
dc.titleMeasurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases
dc.status.refereedYes
dc.date.Accepted2016-10-06
dc.date.application2016-10-07
dc.typeArticle
dc.type.versionAccepted manuscript
dc.identifier.doihttps://doi.org/10.1016/j.plefa.2016.10.003
dc.rights.licenseCC-BY-NC-ND
dc.openaccess.statusopenAccess


Item file(s)

Thumbnail
Name:
watson_et_al_2016.pdf
Size:
824.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record